Identifying predictive biomarkers of cognitive decline is critical for timely intervention in early Alzheimer's disease and related dementia. Biomarkers such as cerebrospinal fluid (CSF) neurofilament light (NfL), and MRI-based hippocampal atrophy are potential indicators of neurodegeneration, but their long-term predictive value remains unclear.
Objective
This study examined 20-year longitudinal associations between CSF NfL, MRI-based hippocampal atrophy, and cognitive decline in cognitively normal older adults.
Methods
A cohort of 279 cognitively normal adults aged ≥55 years was followed from 2003 to 2023 at the Knight ADRC. Participants underwent annual cognitive and neurological assessments, including Clinical Dementia Rating (CDR), CSF NfL quantification, and MRI-based hippocampal volumetry. Cognitive decline was defined as: (1) first progression (CDR ≥ 0.5) and (2) sustained progression (two consecutive CDRs ≥ 0.5). Analyses included Kaplan-Meier survival, Cox proportional hazards models, and linear mixed-effects (LME) models.
Results
Participants had a mean age of 66.5 years (SD = 6.08); 58.4% were female. Mean follow-up was 11.41 years (SD = 3.5). First progression occurred in 71 participants (25.4%), and sustained progression in 35 (13%). Higher CSF NfL levels were associated with faster time to first (95% CI:0.2–1; p < 0.001) and sustained progression (95% CI:0.46–1; p = 0.008). Cox models showed increased risk of first progression (HR = 1.83; 95% CI: 1.11–3.01; p = 0.018) but not sustained (p = 0.093). LME models showed CSF NfL increase and hippocampal volume decline (p < 0.001) in both outcomes.
Conclusions
CSF NfL is a strong predictor of cognitive decline and may serve as a screening biomarker for early dementia risk.
JackCRBennettDABlennowK, et al.NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement2018; 14: 535–562.
2.
DhimanRKThumburuKKVermaN, et al.Comparative efficacy of treatment options for minimal hepatic encephalopathy: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol2020; 18: 800–812.e25.
3.
AarslandDZaccaiJBrayneC. A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord2005; 20: 1255–1263.
Van EldikLJSiemersERCollinsEC, et al.Understanding recent advances in non-amyloid/non-tau (NANT) biomarkers and therapeutic targets in Alzheimer’s disease. Alzheimers Dementia (N Y)2024; 10: e70014.
6.
JackCRPetersenRCXuY, et al.Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology2000; 55: 484–490.
7.
HaassCSelkoeD. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?PLoS Biol2022; 20: e3001694.
8.
DuboisBVillainNFrisoniGB, et al.Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol2021; 20: 484–496.
9.
SallowaySSperlingRFoxNC, et al.Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med2014; 370: 322–333.
10.
Serrano-PozoAQianJMonsellSE, et al.Mild to moderate Alzheimer dementia with insufficient neuropathological changes. Ann Neurol2014; 75: 597–601.
11.
ZhaoYXinYMengS, et al.Neurofilament light chain protein in neurodegenerative dementia: a systematic review and network meta-analysis. Neurosci Biobehav Rev2019; 102: 123–138.
12.
DuboisBPadovaniAScheltensP, et al.Timely diagnosis for Alzheimer’s disease: a literature review on benefits and challenges. J Alzheimers Dis2015; 49: 617–631.
13.
FaganAMRoeCMXiongC, et al.Cerebrospinal fluid tau/β-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol2007; 64: 343.
14.
FaganAMMintunMAMachRH, et al.Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. Ann Neurol2006; 59: 512–519.
15.
ShawLMVandersticheleHKnapik-CzajkaM, et al.Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol2009; 65: 403–413.
16.
De MeyerG. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol2010; 67: 949.
17.
SperlingRAAisenPSBeckettLA, et al.Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement2011; 7: 280–292.
DesikanRSSégonneFFischlB, et al.An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage2006; 31: 968–980.
21.
MurphySAChenLDohertyJM, et al.Cognitive and brain reserve predict decline in adverse driving behaviors among cognitively normal older adults. Front Psychol2022; 13: 1076735.
22.
BucknerRLHeadDParkerJ, et al.A unified approach for morphometric and functional data analysis in young, old, and demented adults using automated atlas-based head size normalization: reliability and validation against manual measurement of total intracranial volume. Neuroimage2004; 23: 724–738.
23.
BeeklyDLRamosEMvan BelleG, et al.The National Alzheimer’s Coordinating Center (NACC) Database: an Alzheimer disease database. Alzheimer Dis Assoc Disord2004; 18: 270–277.
24.
BeeklyDLRamosEMLeeWW, et al.The National Alzheimer’s Coordinating Center (NACC) Database: the uniform data set. Alzheimer Dis Assoc Disord2007; 21: 249–258.
25.
De MeyerSBlujdeaERSchaeverbekeJ, et al.Longitudinal associations of serum biomarkers with early cognitive, amyloid and grey matter changes. Brain2024; 147: 936–948.
26.
Arevalo-RodriguezISmailagicNRoqué-FigulsM, et al.Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev2021; 7: CD010783.
27.
PereiraJBWestmanEHanssonO. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease. Neurobiol Aging2017; 58: 14–29.
28.
UchidaYNishimakiKSoldanA, et al.Acceleration of brain atrophy and progression from normal cognition to mild cognitive impairment. JAMA Netw Open2024; 7: e2441505.
29.
UchidaYHouZGomez-IsazaL, et al.Quantification of perforant path fibers for early detection of Alzheimer’s disease. Alzheimers Dement2025; 21: e70142.
30.
Malek-AhmadiMSuYGhisaysV, et al.Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults. Alzheimers Res Ther2023; 15: 74.
31.
KernSSyrjanenJABlennowK, et al.Association of cerebrospinal fluid neurofilament light protein with risk of mild cognitive impairment among individuals without cognitive impairment. JAMA Neurol2019; 76: 187.
32.
ZetterbergHSkillbäckTMattssonN, et al.Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression. JAMA Neurol2016; 73: 60.
33.
OlssonBPorteliusECullenNC, et al.Association of Cerebrospinal fluid neurofilament light protein levels with cognition in patients with dementia, motor neuron disease, and movement disorders. JAMA Neurol2019; 76: 318.
34.
HampelHToschiNBaldacciF, et al.Alzheimer’s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: aβ1–42, total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement2018; 14: 492–501.
35.
MattssonNInselPSPalmqvistS, et al.Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease. EMBO Mol Med2016; 8: 1184–1196.
36.
LleóAAlcoleaDMartínez-LageP, et al.Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer’s disease continuum in the BIOMARKAPD study. Alzheimers Dement2019; 15: 742–753.
37.
KesterMISchefferPGKoel-SimmelinkMJ, et al.Serial CSF sampling in Alzheimer’s disease: specific versus non-specific markers. Neurobiol Aging2012; 33: 1591–1598.
38.
MielkeMMSyrjanenJABlennowK, et al.Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology2019; 93: e252–e260.
39.
OuY-NHuHWangZ-T, et al.Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer’s disease. Brain Sci Adv2019; 5: 94–105.
40.
PalmqvistSInselPSStomrudE, et al.Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease. EMBO Mol Med2019; 11: e11170.
41.
Van HartenACSmitsLLTeunissenCE, et al.Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology2013; 81: 1409–1416.
42.
SkillbäckTRosénCAsztelyF, et al.Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob Disease: results from the Swedish Mortality Registry. JAMA Neurol2014; 71: 476.
43.
HonigLSKangMSLeeAJ, et al.Evaluation of plasma biomarkers for A/T/N classification of Alzheimer disease among adults of Caribbean Hispanic ethnicity. JAMA Netw Open2023; 6: e238214.
44.
HanssonOCullenNZetterbergH, et al.Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease. Ann Clin Transl Neurol2021; 8: 259–265.
45.
MielkeMMFrankRDDageJL, et al.Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol2021; 78: 1108.
46.
ShenX-NHuangY-YChenS-D, et al.Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status. Transl Psychiatry2021; 11: 585.
47.
ThijssenEHLa JoieRStromA, et al.Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol2021; 20: 739–752.
48.
Mattsson-CarlgrenNJanelidzeSBatemanRJ, et al.Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med2021; 13: e14022.
49.
Mattsson-CarlgrenNJanelidzeSPalmqvistS, et al.Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain2020; 143: 3234–3241.
50.
MoJSiddiquiSMaudsleyS, et al.Classification of Alzheimer diagnosis from ADNI plasma biomarker data. In: Proceedings of the international conference on bioinformatics, computational biology and biomedical informatics. Washington, DC: ACM, 2013, pp.569–574.
51.
ToledoJBVandersticheleHFigurskiM, et al.Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI. Acta Neuropathol2011; 122: 401.
52.
MattssonNAndreassonUZetterbergH, et al.Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol2017; 74: 557.
53.
GaetaniLHöglundKParnettiL, et al.A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther2018; 10: 8.
54.
BrownEMPierceMEClarkDC, et al.Test-retest reliability of FreeSurfer automated hippocampal subfield segmentation within and across scanners. Neuroimage2020; 210: 116563.
55.
BabulalGMQuirozYTAlbensiBC, et al.Perspectives on ethnic and racial disparities in Alzheimer’s disease and related dementias: update and areas of immediate need. Alzheimers Dement2019; 15: 292–312.
56.
BabulalGMZhaWTraniJF, et al.Identifying gaps and barriers in Alzheimer’s disease and related dementia research and management in low- and middle-income countries: a survey of health professionals and researchers. J Alzheimers Dis2024; 101: 1307–1320.
57.
FranzenSNuytemansKBourdageR, et al.Gaps in clinical research in frontotemporal dementia: a call for diversity and disparities–focused research. Alzheimers Dement2023; 19: 5817–5836.
58.
NuytemansKFranzenSBroceIJ, et al.Gaps in biomedical research in frontotemporal dementia: a call for diversity and disparities focused research. Alzheimers Dement2024; 20: 9014–9036.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
